Capricor Therapeutics Inc
CAPR
查看详细走势图
28.437USD
-1.513-5.05%
交易中 （美东）报价延迟15分钟
2.26M总市值
亏损市盈率 TTM
盘中分时
1分
30分
1小时
日k
周k
月k
日k
今天
-5.05%
5天
-2.28%
1月
+1.82%
6月
+283.77%
今年开始到现在
-1.47%
1年
+147.28%
查看详细走势图
TradingKey Capricor Therapeutics Inc股票评分
单位: USD 更新时间: 2026-03-27操作建议
Capricor Therapeutics Inc当前公司基本面数据相对谨慎，最新ESG披露属于行业中等水平。增长潜力很大。当前估值合理，在生物技术与医疗研究行业排名155/391位。机构持股占比非常高，近一月多位分析师给出公司评级为买入。最高目标价53.90。中期看，股价处于平稳状态。近一个月，市场表现较强，技术面评分较高，但较强的走势得没有得到基本面的印证。目前股价在压力位和支撑位之间，可以做区间波段操作。
Capricor Therapeutics Inc评分
压力支撑
由于公司未披露，未能获取相关数据
多维评测
本期评分
上期评分
公司舆情
过去24小时
热度
过冷
过热
看好
Capricor Therapeutics Inc亮点
亮点风险
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
利润高增长
公司净利润处于行业前列，最新年度总收入0.00美元
估值低估
公司最新PE估值-12.79，处于3年历史低位
机构加仓
最新机构持股14.69M股，环比增加0.05%
PRFDX持仓
明星投资者PRFDX持仓，最新持仓市值3.78K
活跃度降低
近期活跃度降低，过去20天平均换手率-0.09
分析师目标
根据
10
位分析师
买入
评级
53.900
目标均价
+79.97%
涨幅空间
数据免责声明：分析师评级与目标价由LSEG提供，仅供参考，不应当作投资建议
Capricor Therapeutics Inc新闻
即将为您带来更多新闻，敬请期待。。。
财务指标
每股收益
由于公司未披露，未能获取相关数据
营业总收入
由于公司未披露，未能获取相关数据
Capricor Therapeutics Inc简介
Capricor Therapeutics, Inc. is a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment and prevention of rare diseases. The Company's program is focused on the development and commercialization of a cell therapy technology comprised of cardiosphere-derived cells (CDCs) for the treatment of Duchenne muscular dystrophy (DMD). Its lead product candidate deramiocel (also referred to as CAP-1002), is an allogeneic cardiac-derived cell therapy. CAP-1002 is advancing through Phase III clinical development for the treatment of Duchenne muscular dystrophy (DMD). CAP-1002 demonstrates immunomodulatory, antifibrotic, and regenerative actions specifically tailored for dystrophinopathies and heart disease. It leverages its exosome technology, using its StealthX platform in preclinical development focused on the areas of vaccinology, targeted delivery of oligonucleotides, proteins, and small molecule therapeutics.
公司代码CAPR
公司Capricor Therapeutics Inc
CEOMarban (Linda)
网址https://capricor.com/
相关品种
